Changes in tear volume and ocular symptoms of patients receiving oral anticancer drug S-1
Abstract Background Most eye disorders are not fatal but may deteriorate the quality of life of a patient. The eye disorder that is most frequently reported in the cancer chemotherapy is associated with the combination of tegafur/gimeracil/potassium oxonate (S-1). However, preventive methods or trea...
Main Authors: | Reiko Kuriki, Tsuyoshi Hata, Kinuyo Nakayama, Yuichi Ito, Kazunari Misawa, Seiji Ito, Michiko Tatematsu, Norio Kaneda |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-02-01
|
Series: | Journal of Pharmaceutical Health Care and Sciences |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40780-018-0100-8 |
Similar Items
-
Pharmacokinetic and bioequivalence study between two formulations of S-1 in Korean gastric cancer patients
by: Lee HW, et al.
Published: (2019-09-01) -
Effect of the preoperative docetaxel combined with S-1 chemotherapy on the oncogene expression in advanced gastric cancer lesion
by: E-Yi Ben, et al.
Published: (2017-11-01) -
Tegafur/gimeracil/oteracil (TS-1) induced Stevens–Johnson syndrome: Case report
by: Satoko Minakawa, et al.
Published: (2013-09-01) -
Effect of Sipjeondaebo-Tang on the Pharmacokinetics of S-1, an Anticancer Agent, in Rats Evaluated by Population Pharmacokinetic Modeling
by: Tae Hwan Kim, et al.
Published: (2017-09-01) -
Effect of Tegafur Gimeracil Oteracil Potassium Capsule + Kangai injection + intensity-modulated radiation therapy on the cellular malignant biological processes in advanced cervical cancer lesion
by: Ji-Fan Yang, et al.
Published: (2017-09-01)